Kalaris Therapeutics grants 18,000 stock options

Kalaris Therapeutics, Inc. reported that director Laurie Keating received a grant of stock options covering 18,000 shares of common stock, with a $3.51 exercise price and expiring on July 31, 2036.

Accepted by SEC EDGAR 08/03/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. reported that director Laurie Keating received a grant of stock options covering 18,000 shares of common stock, with a $3.51 exercise price and expiring on July 31, 2036. The options vest in equal monthly installments over three years from August 1, 2026 through August 1, 2029, subject to continuous service, resulting in 18,000 options directly held after this award.

Insider Trade Summary

Grant/Award: 18,000 shares

Grant/Award 1 txn

Insider KEATING LAURIE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	18,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 18,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service.

Key Figures

Stock options granted: 18000.0000 options Exercise price: $3.5100 per share Expiration date: 2036-07-31 +3 more

6 metrics

Stock options granted 18000.0000 options Grant to director Laurie Keating on August 1, 2026

Exercise price $3.5100 per share Exercise price of the stock option award

Expiration date 2036-07-31 Option expiration date for the granted stock options

Underlying shares 18000.0000 shares Common shares underlying the granted stock options

Vesting start date August 1, 2026 Vesting begins on this date in equal monthly installments

Vesting end date August 1, 2029 Final vesting date, subject to continuous service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, continuous service

4 terms

Stock Option (Right to Buy) financial

"Security titled "Stock Option (Right to Buy)" was granted."

exercise price financial

"The option has a conversion or exercise price of $3.5100 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares underlying the option are scheduled to vest over three years."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service other

"Vesting runs through August 1, 2029, subject to continuous service."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KLRS report for director Laurie Keating?

Kalaris Therapeutics (KLRS) reported that director Laurie Keating received a grant of stock options covering 18,000 shares of common stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.

How many Kalaris Therapeutics (KLRS) stock options did Laurie Keating receive?

Laurie Keating was granted 18,000 stock options linked to an equal number of common shares of Kalaris Therapeutics. These options were reported as directly owned following the transaction and represent a new equity-based compensation award.

What is the exercise price and expiration date of Laurie Keating’s KLRS options?

The stock options granted to Laurie Keating have a $3.51 exercise price per share and expire on July 31, 2036. This sets the price at which she can purchase KLRS common stock before the expiration date, subject to vesting and service conditions.

How do Laurie Keating’s KLRS stock options vest over time?

The 18,000 KLRS stock options granted to Laurie Keating are scheduled to vest over three years in equal monthly installments. Vesting runs from August 1, 2026 through August 1, 2029 and is conditioned on her continuous service with the company.

Was Laurie Keating’s KLRS option grant made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox was not marked as affirmative, and there is no footnote indicating a trading plan. This grant appears as standard equity compensation rather than a transaction executed under a pre-arranged 10b5-1 plan.

What ownership type is reported for Laurie Keating’s new KLRS stock options?

The 18,000 stock options granted to Laurie Keating are reported as directly owned. There is no indication they are held through a trust, fund, or other indirect entity, and no footnote disclaims her beneficial ownership of this award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KEATING LAURIE

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.51	08/01/2026		A		18,000		(1)	07/31/2036	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service.

	/s/ Andrew Oxtoby, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)